[口試公告] 113-2碩士學位論文口試
| 學生姓名 | 口試時間 | 論文題目 |
| 張璇 CHANG, HSUAN |
2025/07/25 | 探討口服 fluoroquinolones 與精神疾病之關聯性： 一項回溯性世代研究 Association between oral fluoroquinolones and psychiatric disorders: a retrospective cohort study |
| 徐語瞳 HSU,YU-TUNG |
2025/07/24 | 荔枝果皮及種子之化學成分及生物活性研究 Studies on the Chemical Constituents and Biological Activities of the Pericarp and Seed of Litchi chinensis |
| 李玉琦 LEE, YU-CHI |
2025/07/18 | 核仁素靶向的奈米載體調節腫瘤微環境達到三陰性乳癌的治療 Modulation of the Tumor Microenvironment by Nucleolin-Targeting Nanoparticle Therapy for Triple-Negative Breast Cancer |
| 魏杰俊 WEI, CHIEH-CHUN |
2025/07/17 | 應用於酚類化合物液相層析-質譜分析的創新含硼衍生化策略 Improved LC-MS Detection of Phenolic Compounds via a Novel Boron-Containing Derivatization Method |
| 吳宗錡 WU, TSUNG-CHI |
2025/07/15 | 探討潛在不適當處方與非預期性住院在臺灣一般老年族群之關聯性：一項病例-病例-時間-對照研究 Investigation of the association between potentially inappropriate prescribing and unplanned hospitalization among the general older population in Taiwan: a case-case-time-control study |
| 林婉芸 LIN, WAN-YUN |
2025/07/04 | 苯丙胺酸經溶劑介導褐化後形成奈米粒子之探討 Investigation of Nanoparticle Formation by Solvent-Mediated Browning Reaction of Phenylalanine |
| 高瑮宇 KAO, LI-YU |
2025/07/03 | 評估SGLT2 Inhibitors用於接受蒽環類藥物治療的第二型糖尿病病人之心臟保護效果：一個回溯性的世代研究 Assessing the Cardioprotective Effects of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Anthracycline Therapy: A Retrospective Cohort Study |
| 林亭妤 LIN, TING-YU |
2025/07/02 | 探討氫離子幫浦抑制劑與第二型組織胺受體拮抗劑對合併上消化道共病病人之偏頭痛嚴重程度的影響 Investigation of the Effects of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists on Migraine Severity in Patients with Upper Gastrointestinal Comorbidities |
| 連欣 LIEN,HSIN |
2025/07/02 | 女性乳癌病人使用CDK4/6抑制劑與心毒性發生風險之關聯性 Association Between CDK4/6 Inhibitors and Risk of Cardiotoxicity in Women with Breast Cancer |
| 趙苡雯 CHAO, YI-WEN |
2025/06/30 | 荷爾蒙療法對於乳癌病人心血管代謝結果的比較：以全國人口為對象之研究 Comparative Analysis of Cardiometabolic Outcomes in Breast Cancer Patients Receiving Endocrine Therapy: A Nationwide Population-Based Cohort Study |
| 謝心瑜 HSIEH, HSIN-YU |
2025/06/27 | 評估接受經皮冠狀動脈介入治療的心房顫動病人使用抗血栓藥物的療效與安全性 Evaluating the Effectiveness and Safety of Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention |
| 李怡欣 LEE, YI-SIN |
2025/06/26 | Isavuconazole 與 Voriconazole 用於侵襲性麴菌病先發性及確認性治療之 42 天住院死亡率比較：單中心回溯性世代研究 Comparison of 42-Day In-Hospital Mortality Between Isavuconazole and Voriconazole for Preemptive and Definitive Treatment of Invasive Aspergillosis: A Single-Center Retrospective Cohort Study |
| 林佩璉 LIN, PEI-LIEN |
2025/06/12 | 台灣BRCA基因突變型轉移型去勢抗性前列腺癌病人使用第一線療法 PARP 抑制劑 Olaparib 或 Niraparib 合併 Abiraterone 或單用 Abiraterone 之成本效果分析 Cost-Effectiveness Analysis of Olaparib and Niraparib With Abiraterone Versus Abiraterone for First-Line Treatment of BRCA Mutated Metastatic Castration-Resistant Prostate Cancer in Taiwan |
| 孟欣妤 MENG, HSIN-YU |
2025/05/29 | 台灣EGFR突變非小細胞肺癌病人使用第一線療法 Amivantamab 合併 Lazertinib 或 Osimertinib 之成本效果分析
Cost-Effectiveness Analysis of Amivantamab with Lazertinib Versus Osimertinib as First-Line Therapy for EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (NSCLC) in Taiwan |
| 蔡小童 TSAI, HSIAO-TUNG |
2025/05/29 | 臺灣第II到IIIA期PD-L1表現≥ 1%且不適用標靶治療之可切除非小細胞肺癌病人使用免疫檢查點抑制劑Atezolizumab或Pembrolizumab輔助性治療之成本效果分析 Cost-effectiveness Analysis of Adjuvant Atezolizumab or Pembrolizumab in Resectable Stage II–IIIA Non–Small Cell Lung Cancer Patients with PD-L1 ≥1% Expression and Ineligible for TKI Therapy in Taiwan |
~ 2025/07/01更新